News
06-05-2017, 10:32 PM
A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest.
More... (http://www.news-medical.net/news/20170606/Adding-a-second-HER2-targeted-treatment-may-improve-outcomes-for-some-women-with-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20170606/Adding-a-second-HER2-targeted-treatment-may-improve-outcomes-for-some-women-with-breast-cancer.aspx)